“Dr. Wang Yongzhong brings over 20 years of innovation and leadership experience in global pharmaceutical and biotech industries. Dr. Wang is leading the corporate strategic direction and oversees the operations of CMAB”
Dr. Wang will bring over 20 years of innovation and leadership experience in global pharmaceutical and biotech industries.
He most recently held a role of President of Pharmaceuticals and EVP at Simcere, where he oversaw all pilot and commercial manufacturing operations including a Mab facility and a recombinant protein facility. He was also responsible for all quality operations including R&D, production and distribution, supply chain, engineering, regulatory affairs, and international sales. Among other duties, he also served as the Chairman of the Board for a joint venture for therapeutic DNA vaccines and on the joint steering committee for Simcere's strategic partnership in biosimilar with AMGEN.
Prior to Simcere, he served as the CEO at Kanghong Biotech, which successfully developed and launched Conbercept, the first innovative biological product with an international non-propriety name from China in 2014. Under his leadership, Conbercept became the market leader over international brands in China market in 2016. Dr. Wang further brought Conbercept to the global stage by clearing a FDA IND to directly enter phase III clinical trial in the USA, the first such case for innovative biological product from China. This achievement was voted as one of China's Top Ten Advancements in Pharmaceutical and Biotech Industries in 2016.
Earlier in his career, Dr. Wang worked at Genzyme in Cambridge, USA. He led CMC and quality projects for Carticel and Epicel, the first two approved cell therapy products by the FDA. He was also instrumental for the development and approval of MACI, the first issue-engineering product approved by FDA. He held two patents for MACI, both of which were used for commercial manufacturing.
Dr. Wang earned his PhD from the Chemicaland Biological Engineering Department at Tufts University in Boston and hisscientific publications have obtained over 3000 citations by peers in the biotech field.
"With more than two decades of international experience in the pharmaceutical and biotech industry, Michael Frizberg is responsible for CMAB's global strategy and business development."
With more than two decades of international experience in the pharmaceutical and biotech industry, Michael Frizberg is responsible for CMAB's global strategy and business development.
Michael's career started in Hong Kong in 1995, followed by various senior positions at Sanofi-Aventis including Global Supply Chain and Global Market Research responsibilities before joining Lonza.
At Lonza Michael led several key global functions including Marketing, Corporate Communications, Investor Relations, Business Development and Sales. His initiative to create a biosmilar-driven business unit through a joint venture with one of the leading pharmaceutical companies in the world was, at the time, a major strategic move for Lonza and the industry. He also served for several years as the Chairman to the Board of a Swiss-Chinese pharmaceutical venture, which he established in 2012.
Immediately before joining CMAB, Michael was General Manager of the European division of Luye Pharma.
Michael holds a Master of Arts in Economics from Wayne State University (USA) as well as a Diplom Kaufmann (MBA) from University of Augsburg (Germany).